Piśmiennictwo

1. Rocznik Statystyczny Rzeczypospolitej Polskiej 2012. http://www.stat.gov.pl/cps/rde/xbcr/gus/RS_rocznik_statystyczny_rp_2012.pdf

2. Lloyd-Jones DM, Evans JC, Levy D. Epidemiology of hypertension in the old-old: data from the community in the 1990s. Am J Hypertens 2004; 17: 200A.

3. National High Blood Pressure Education Program Working Group: National High Blood Pressure Education Program Working Group report on hypertension in the elderly. Hypertension 1994; 23: 275-285.

4. Asmar R, Topouchian J, Pannier B, et al. Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study. J Hypertens 2001; 19: 813-818.

5. Franklin SS, Gustin WG, Wong ND. Hemodynamic patterns of age-related changes in blood pressure: the Framingham Heart Study. Circulation 1997; 96: 308-315.

6. Szwench E. Charakterystyka kliniczna chorych z opornym nadciśnieniem tętniczym. Praca doktorska. Instytut Kardiologii, Warszawa 2012.

7. Bulpitt CJ, Fletcher AE. Prognostic significance of blood pressure in the very old. Implications for the treatment decision. Drugs Aging. 1994; 5: 184-191.

8. Messerli F. INVEST: J shape curve in hypertensive patients with coronary artery disease. Prezentacja ustna. 52 Meeting ACC. New Orlean 2004.

9. Gueyffier F, Bulpitt C, Boissel JP, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet. 1999; 353: 793-796.

10. Beckett NS, Peters R, Fletcher AE, et al., HYVET Study Group. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med. 2008; 358: 1887-1898.

11. US Food and Drug Administration. Clinical Briefing Document: New Drug Application 22580: VI-0521 QNEXA (phentermine/topramate). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM292315.pdf. Accessed August 2, 2012.

12. FDA Briefing Document: NDA 200063: Contrave (Naltrexone 4mg, 8 mg/Bupropion HCL 90mg extended release tablet). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM235671.pdf. Accessed August 2, 2012.

13. Proceedings from the Endocrinologic and Metabolic Drugs Advisory Committee meeting: Addendum to the FDA Briefing Document for Lorcaserin. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm303193.htm. Accessed August 2, 2012.

14. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005; 91 (Suppl. 5): v1-v52.

15. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007; 28: 1462-1536.

16. Amery A, Birkenhager WH, Bulpit CJ, et al. The European Working Party on High blood pressure in the Elderly. Am J Med 1991; 1 (90 Suppl.): 1S-64S.

17. SHEP Cooperative Research Group. Prevention of stroke by drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program. (SHEP) JAMA 1991; 265: 3255-3264.

18. Mancia G, Ruilop L, Palmer C, et al. Effects of nifedipine GITS and diuretics in isolated systolic hypertension – a subanalysis of the INSIGHT study. Blood Press 2004; 13: 310.

19. MRC working party Medical Research Council trial of treatment of hypertrnsion in older adults: principal results. BMJ 1992; 304: 405-412.

20. Staessen JA, Wang JG, Thijs L. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet 1997; 350: 757-764.

21. Hanson L, Lindholm LH, Ekbom T. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-1756.

22. Dahlof B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.

23. Findings of the "Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial" (ALLHAT); http://allhat.sph.uth.tmc.edu/; http://www.nhlbi.nih.gov/health/allhat/facts.htm.

24. Williams B. Recent hypertension trials. Implications and controversies. JACC 2005; 45: 813-827.

25. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121-1123.

26. Grodzicki T, Gryglewska B, Tomasik T i wsp. Zasady postępowania w nadciśnieniu tętniczym. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego oraz Kolegium Lekarzy Rodzinnych w Polsce. Nadciśnienie Tętnicze 2008; 5: 317-342.

27. Grodzicki T. Nowe możliwości terapii skojarzonej nadciśnienia tętniczego u osób starszych — telmisartan i amlodypina. Gerontologia Polska 2011; 3–4: 127–133.

28. Kato J, Yokota N, Tamaki N, et al. Differential blood pressure reductions by angiotensin receptor blocker plus calcium channel blocker or diuretic in elderly hypertension with or without obesity. Journal of the American Society of Hypertension 2012; Vol. 6, Issue 6; 393-398.

29. Maule S, Papotti G, Naso D, et al. Orthostatic hypotension: evaluation and treatment. Cardiovasc Hematol Disord Drug Targets. 2007; 7: 63-70.

30. Rutan GH, Hermanson B, Bild DE, et al. Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Hypertension 1992; 19: 508-519.

31. Ooi WL, Barrett S, Hossain M, et al. Patterns of orthostatic blood pressure change and their clinical correlates in a frail, elderly population. http://www.ncbi.nlm.nih.gov/pubmed/9109468 JAMA 1997; 277: 1299-1304.

32. Masaki KH, Schatz IJ, Burchfiel CM, et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. Circulation 1998; 98: 2290-2295.

33. Fedorowski A, Hedblad B, Engström G, et al. Orthostatic hypotension and long-term incidence of atrial fibrillation: the Malmö Preventive Project. J Intern Med 2010; 268: 383-389.

34. Patel AY, Shah P, Flaherty JH. Number of medications is associated with outcomes in the elderly patient with metabolic syndrome. Journal of Geriatric Cardiology 2012; 9: 213-219.

35. Beckett NS, Peters R, Fletcher AE, et al. Treatment of Hypertension in Patients 80 Years of Age or Older. NEJM 2008; 358: 1887-1898.

36. Bulpitt CJ, Beckett N, Peters R, et al. Does white coat hypertension require treatment over age 80?: Results of the hypertension in the very elderly trial ambulatory blood pressure side project. Hypertension 2013; 61: 89-94.

37. Peters R, Beckett N, Forette F, et al. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008; 7(8): 683-689.

38. Beckett N, Peters R, Tuomilehto J, et al. HYVET Study Group. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ 2012; 344: d7541.

39. Peters R, Beckett N. Hypertension, dementia, and antihypertensive treatment: implications for the very elderly. Curr Hypertens Rep 2009; 11(4): 277-282.

40. McGuinness B, Todd S, Passmore P, et al. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst Rev 2006; (2): CD004034.

41. Chang-Quan H, Hui W, Chao-Min W, et al. The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta-analysis of longitudinal studies. Int J Clin Pract. 2011; 65(12): 1295-1305.

42. Ma C, Cao J, Lu XC, et al. Cardiovascular and cerebro-vascular outcomes in elderly hypertensive patients treated with either ARB or ACEI. J Geriatr Cardiol. 2012; 9(3): 252-257.

43. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other firstline antihypertensive therapies: a meta-analysis of randomized controlled trials. Lancet 2000; 356: 1949-1954.

44. Shinohara Y, Origasa H. Post-stroke pneumonia prevention by angiotensin-converting enzyme inhibitors: results of a meta-analysis of five studies in Asians. Adv Ther 2012; 29(10): 900-912.

45. Caldeira D, Alarcão J, Vaz-Carneiro A, et al. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ 2012; 345: e4260.